RNAscope in situ hybridization-based method for detecting DUX4 RNA expression in vitro
- 1Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio 43205, USA
- 2Department of Pediatrics, The Ohio State University, Columbus, Ohio 43205, USA
- Corresponding author: Scott.Harper{at}nationwidechildrens.org
Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is among the most common forms of muscular dystrophy. FSHD is caused by aberrant expression of the toxic DUX4 gene in muscle. Detecting endogenous DUX4 in patient tissue using conventional methods can be challenging, due to the low level of DUX4 expression. Therefore, developing simple and trustworthy DUX4 detection methods is an important need in the FSHD field. Here, we describe such a method, which uses the RNAscope assay, an RNA in situ hybridization (ISH) technology. We show that a custom-designed RNAscope assay can detect overexpressed DUX4 mRNA in transfected HEK293 cells and endogenous DUX4 mRNA in FSHD patient-derived myotubes. The RNAscope assay was highly sensitive for tracking reductions in DUX4 mRNA following treatment with our therapeutic mi405 microRNA, suggesting that RNAscope-based DUX4 expression assays could be developed as a prospective outcome measure in therapy trials. This study could set the stage for optimizing and developing a new, rapid RNA ISH-based molecular diagnostic assay for future clinical use in the FSHD field.
Keywords
Footnotes
-
Article is online at http://www.rnajournal.org/cgi/doi/10.1261/rna.070177.118.
-
Freely available online through the RNA Open Access option.
- Received December 21, 2018.
- Accepted June 7, 2019.
- © 2019 Amini Chermahini et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society
This article, published in RNA, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.










